Clinical pharmacy service practice in a Chinese tertiary hospital

References

1. American College of Clinical pharmacy (ACCP). The definition of clinical pharmacy. Pharmacotherapy 2008;28:816–7.10.1592/phco.28.6.816Search in Google Scholar PubMed

2. European Society of Clinical Pharmacy. What is clinical pharmacy? Available at: http://www.escpweb.org/cms/Clinical_ pharmacy (2010).Search in Google Scholar

3. MacLaren R, Bond CA, Martin SJ, Fike D. Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections. Crit Care Med 2008;36:3184–9.10.1097/CCM.0b013e31818f2269Search in Google Scholar PubMed

4. De Rijdt T, Willems L, Simoens S. Economic effects of clinical pharmacy interventions: a literature review. Am J Health Syst Pharm 2008;65:1161–72.10.2146/ajhp070506Search in Google Scholar PubMed

5. Anderson SV, Schumock GT. Evaluation and justification of clinical pharmacy services. Expert Rev Pharmacoecon Outcomes Res 2009;9:539–45.10.1586/erp.09.57Search in Google Scholar PubMed

6. Anderson S. The state of the world’s pharmacy: a portrait of the pharmacy profession. J Interprof Care 2002;16:391–404.10.1080/1356182021000008337Search in Google Scholar PubMed

7. Nissen L. Current status of pharmacist influences on prescribing of medicines. Am J Health Syst Pharm 2009;66:S29–34.10.2146/ajhp080607Search in Google Scholar PubMed

8. Ministry of Health of the People’s Republic of China. Policy on Pharmacy Administration in Health Care Facilities. Available at: http://www.moh.gov.cn/mohyzs/s3585/201103/51113.shtml (in Chinese; 2011).Search in Google Scholar

9. Ministry of Health of the People’s Republic of China. National Accreditation Criteria for Tertiary Hospitals. Available at: http://www.moh.gov.cn/yzygj/s3585u/201104/c6fa4cc981d4429ba8caa7666aa13710.shtml (in Chinese; 2011).Search in Google Scholar

10. Sun S. Status quo and future of clinical pharmacists in China. Chin Pharm 2007;1:1–3.Search in Google Scholar

11. Gillespie U, Alassaad A, Henrohn D, Garmo H, Hammarlund-Udenaes M, Toss H, et al. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older. Arch Intern Med 2009;169:894–900.10.1001/archinternmed.2009.71Search in Google Scholar PubMed

12. Jiang SP, Chen J, Zhang XG, Lu XY, Zhao QW. Implementation of pharmacists’ interventions and assessment of medication errors in an intensive care unit of a Chinese tertiary hospital. Ther Clin Risk Manag 2014;10:861–6.10.2147/TCRM.S69585Search in Google Scholar

13. Santucci R, Levêque D, Herbrecht R, Fischbach M, Gérout AC, Untereiner C, et al. Medication adverse events: impact of pharmaceutical consultations during the hospitalization of patients. Ann Pharm Fr 2014;72:440–50.10.1016/j.pharma.2014.05.003Search in Google Scholar PubMed

14. Michalets E, Creger J, Shillinglaw WR. Outcomes of expanded use of clinical pharmacist practitioners in addition to team-based care in a community health system intensive care unit. Am J Health Syst Pharm 2015;72:47–53.10.2146/ajhp140105Search in Google Scholar PubMed

15. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014;11:CD000011.10.1002/14651858.CD000011.pub4Search in Google Scholar PubMed PubMed Central

16. Avery M, Williams F. The importance of pharmacist providing patient education in oncology. J Pharm Pract 2015;28:26–30.10.1177/0897190014562382Search in Google Scholar

17. Calloway S, Akilo HA, Bierman K. Impact of a clinical decision support system on pharmacy clinical interventions, documentation efforts, and costs. Hosp Pharm 2013;48:744–52.10.1310/hpj4809-744Search in Google Scholar

18. Hu M, Yee G, Zhou N, Yang N, Jiang X, Klepser D. Development and current status of clinical pharmacy education in China. Am J Pharm Educ 2014;78:157.10.5688/ajpe788157Search in Google Scholar

19. Yao K, Yang Y. Streptococcus pneumoniae diseases in Chinese children: past, present and future. Vaccine 2008;26:4425–33.10.1016/j.vaccine.2008.06.052Search in Google Scholar

20. Yip WC, Hsiao WC, Chen W, Hu S, Ma J, Maynard A. Early appraisal of China’s huge and complex health-care reforms. Lancet 2012;379:833–42.10.1016/S0140-6736(11)61880-1Search in Google Scholar

21. Zou XX, Fang Z, Min R, Bai X, Zhang Y, Xu D, et al. Is nationwide special campaign on antibiotic stewardship program effective on ameliorating irrational antibiotic use in China? Study on the antibiotic use of specialized hospitals in China in 2011-2012. J Huazhong Univ Sci Technol Med Sci 2014;34:456–63.10.1007/s11596-014-1300-6Search in Google Scholar PubMed

22. Burke JP. Maximizing appropriate antibiotic prophylaxis for surgical patients: an update from LDS Hospital, Salt Lake City. Clin Infect Dis 2001;33:78.10.1086/321861Search in Google Scholar PubMed

23. American Society of Health-System Pharmacists (ASHP). ASHP therapeutic guidelines on antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 1999;56:1839–88.10.1093/ajhp/56.18.1839Search in Google Scholar PubMed

24. Choi WS, Song JY, Hwang JH, Kim NS, Cheong HJ. Appropriateness of antibiotic prophylaxis for major surgery in Korea. Infect Control Hosp Epidemiol 2007;28:997–1002.10.1086/519180Search in Google Scholar PubMed

25. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999;20:250–78.10.1086/501620Search in Google Scholar

26. Jiang L, Shi T, Shen A, Sun Y, Du D, Ge W-H. Intervention management on prophylactic use of antibiotics during perioperative period of type I surgical incision operations. Chin J Nosocomio 2010;19:1296–9.Search in Google Scholar

27. Von Gunten V, Reymond JP, Beney J. Clinical and economic outcomes of pharmaceutical services related to antibiotic use: a literature review. Pharm World Sci 2007;29:146–63.10.1007/s11096-006-9042-6Search in Google Scholar PubMed

28. Shen J, Sun Q, Zhou X, Wei Y, Qi Y. Pharmacist interventions on antibiotic use in inpatients with respiratory tract infections in a Chinese hospital. Int J Clin Pharm 2011;33:929–33.10.1007/s11096-011-9577-zSearch in Google Scholar PubMed

29. Zhang L, Yan J, Liu X, Ye Z, Yang X, Meyboom R, et al. Pharmacovigilance practice and risk control of traditional Chinese medicine drugs in China: current status and future perspective. J Ethnopharmacol 2012;140:519–25.10.1016/j.jep.2012.01.058Search in Google Scholar PubMed

30. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study. Br Med J 1998;317:119–20.10.1136/bmj.317.7151.119Search in Google Scholar PubMed PubMed Central

31. Alvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Arias LH. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol 1998;54:483–8.10.1007/s002280050498Search in Google Scholar PubMed

32. Watson I, Potter J, Yatscoff R, Fraser A, Himberg JJ, Wenk M. Therapeutic drug monitoring. Drug Monit 1997;19:125.10.1097/00007691-199704000-00001Search in Google Scholar

33. Zhao W, Jacqz-Aigrain E. Principles of therapeutic drug monitoring. Handb Exp Pharmacol 2011;205:77–90.10.1007/978-3-642-20195-0_3Search in Google Scholar PubMed

34. Adaway JE, Keevil BG. Therapeutic drug monitoring and LC-MS/MS. J Chromatogr B 2012;883–884:33–49.10.1016/j.jchromb.2011.09.041Search in Google Scholar PubMed

35. Schutz E, Shipkova M, Armstrong VW, Wieland E, Oellerich M. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 1999;45:419–22.10.1093/clinchem/45.3.419Search in Google Scholar

36. Bullingham R, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transpl Proc 1996;28:925–9.Search in Google Scholar

37. Holt DW. Monitoring mycophenolic acid. Ann Clin Biochem 2002;39:173–83.10.1258/0004563021902035Search in Google Scholar PubMed

38. Patel CG, Akhlaghi F. High-performance liquid chromatography method for the determination of mycophenolic acid and its acyl and phenol glucuronide metabolites in human plasma. Ther Drug Monit 2006;28:116–22.10.1097/01.ftd.0000177664.96726.56Search in Google Scholar PubMed

39. Chen B, Zhang WX, Yu ZC, Cai WM. Determination of mycophenolic Acid (MPA) and its acyl and phenol glucuronide metabolites simultaneously in human plasma by a simplified HPLC method. Anal Lett 2007;40:2465–75.10.1080/00032710701583466Search in Google Scholar

40. Brandhorst G, Streit F, Goetze S, Oellerich M, Armstrong VW. Quantification by liquid chromatography tandem mass spectrometry of mycophenolic acid and its phenol and acyl glucuronide metabolites. Clin Chem 2006;52:1962–4.10.1373/clinchem.2006.074336Search in Google Scholar

41. Klepacki J, Klawitter J, Bendrick-Peart J, Schniedewind B, Heischmann S, Shokati T, et al. A high-throughput U-HPLC-MS/MS assay for the quantification of mycophenolic acid and its major metabolites mycophenolic acid glucuronide and mycophenolic acid acyl-glucuronide in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 883–884:113–9.10.1016/j.jchromb.2011.07.021Search in Google Scholar

42. Aresta A, Palmisano F, Zambonin CG, Schena P, Grandaliano G. Simultaneous determination of free mycophenolic acid and its glucuronide in serum of patients under mycophenolate mophetil therapy by ion-pair reversed-phase liquid chromatography with diode array UV detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004;810:197–202.10.1016/S1570-0232(04)00620-8Search in Google Scholar

43. Shen J, Jiao Z, Yu YQ, Zhang M, Zhong MK. Quantification of total and free mycophenolic acid in human plasma by liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2005;817:207–13.10.1016/j.jchromb.2004.12.005Search in Google Scholar PubMed

44. Chen B, Gu ZD, Chen H, Zhang WX, Fen XJ, Cai WM, et al. Establishment of HPLC fluorescence and EMIT methods for determination of free mycophenolic acid and its application in Chinese liver transplant recipients. Ther Drug Monit 2010;32:653–60.10.1097/FTD.0b013e3181f01397Search in Google Scholar PubMed

45. Patel CG, Mendonza AE, Akhlaghi F, Majid O, Trull AK, Lee T, et al. Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004;813:287–94.10.1016/j.jchromb.2004.10.004Search in Google Scholar PubMed

46. Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003;63:1247–97.10.2165/00003495-200363120-00006Search in Google Scholar PubMed

47. Liu XX, Chen ZJ, Hu SS, Chen B. Determination of tacrolimus in whole blood by liquid chromatographic-tandem mass spectrometry and application in pharmacokinetic study of liver transplant patients. Pharm Clin Res 2013;21:329–33.Search in Google Scholar

48. Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D, et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008;14:220–8.10.1016/j.bbmt.2007.10.028Search in Google Scholar PubMed

49. Ansari M, Théoret Y, Rezgui MA, Peters C, Mezziani S, Desjean C, et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. Ther Drug Monit 2014;36:93–9.10.1097/FTD.0b013e3182a04fc7Search in Google Scholar PubMed

50. Zhang H, Graiser M, Hutcherson DA, Dada MO, McMillan S, Ali Z, et al. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 2012;18:1287–94.10.1016/j.bbmt.2012.02.006Search in Google Scholar PubMed

51. Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, et al. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol 2010 6;3:36.10.1186/1756-8722-3-36Search in Google Scholar PubMed PubMed Central

52. Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 2006;57:191–8.10.1007/s00280-005-0029-0Search in Google Scholar PubMed

53. Huang JJ, Chen B, Yang WH. Establishment of an LC-MS/MS method for the determination of busulfan in human plasma. Chin J Pharm Anal 2013;33:737–42.Search in Google Scholar

54. Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 1998;56:1019–38.10.2165/00003495-199856060-00006Search in Google Scholar PubMed

55. Ting LS, Villeneuve E, Ensom MH. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit 2006;28:419–30.10.1097/01.ftd.0000211810.19935.44Search in Google Scholar PubMed

56. van den Bongard HJ, Mathôt RA, Beijnen JH, Schellens JH. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 2000;39:345–67.10.2165/00003088-200039050-00004Search in Google Scholar PubMed

57. Zhou PJ, Xu D, Yu ZC, Wang XH, Shao K, Zhao JP. Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients. Clin Pharmacokinet 2007;46:389–401.10.2165/00003088-200746050-00002Search in Google Scholar PubMed

58. Chen H, Peng C, Yu Z, Shen B, Deng X, Qiu W, et al. Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. Clin Pharmacokinet 2007;46:175–85.10.2165/00003088-200746020-00005Search in Google Scholar PubMed

59. Hao C, Erzheng C, Anwei M, Zhicheng Y, Baiyong S, Xiaxing D, et al. Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients. Liver Transpl 2007;13:1684–93.10.1002/lt.21293Search in Google Scholar PubMed

60. Chen H, Gu Z, Chen B, Mao H, Zhang W, Fan Q. Models for the prediction of mycophenolic acid area under the curve using a limited-sampling strategy and an enzyme multiplied immunoassay technique in Chinese patients undergoing liver transplantation. Clin Ther 2008;30:2387–401.10.1016/j.clinthera.2008.12.017Search in Google Scholar PubMed

61. Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998;9:1511–20.10.1681/ASN.V981511Search in Google Scholar

62. Atcheson BA, Taylor PJ, Mudge DW, Johnson DW, Hawley CM, Campbell SB, et al. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol 2005;59:271–80.10.1111/j.1365-2125.2004.02235.xSearch in Google Scholar

63. Gu ZD, Chen B, Song YY, Shen BY, Zhu ZC, Zhang WX, et al. Pharmacokinetics of free mycophenolic acid and limited sampling strategy for the estimation of area under the curve in liver transplant patients. Eur J Pharm Sci 2012;47:636–41.10.1016/j.ejps.2012.08.001Search in Google Scholar

64. Huang JJ, Chen B, Wang L, Tang W, Hu J, Yang WH. Study of clinical pharmacokinetics of intravenous busulfan in adult patients undergoing allogeneic hematopoietic stem cell transplantation. Chin Pharm J 2014;33:737–42.Search in Google Scholar

65. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 1972;5:411–59.10.1016/0010-4809(72)90051-1Search in Google Scholar

66. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit 2001;23:100–14.10.1097/00007691-200104000-00003Search in Google Scholar PubMed

67. Thomson H, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992;22:447–67.10.2165/00003088-199222060-00004Search in Google Scholar PubMed

68. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. N Engl J Med 1986;314:1219–25.10.1056/NEJM198605083141904Search in Google Scholar PubMed

69. Ponticelli C, Minetti L, Di Palo FQ, Vegeto A, Belli L, Corbetta G, et al. The Milan clinical trial with cyclosporine in cadaveric renal transplantation. A three-year follow-up. Transplantation 1988;45:908–13.10.1097/00007890-198805000-00013Search in Google Scholar PubMed

70. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988;46:631–44.10.1097/00007890-198811000-00002Search in Google Scholar PubMed

71. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002;2:148–56.10.1034/j.1600-6143.2002.020206.xSearch in Google Scholar PubMed

72. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P. Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 1998;66:1621–7.10.1097/00007890-199812270-00009Search in Google Scholar

73. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002;24:479–86.10.1097/00007691-200208000-00003Search in Google Scholar

74. Marquet P. Clinical application of population pharmacokinetic methods developed for immunosuppressive drugs. Ther Drug Monit 2005;27:727–32.10.1097/01.ftd.0000179848.65266.aaSearch in Google Scholar

75. Chen B, Zhang W, Gu Z, Li J, Zhang Y, Cai W. Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients. Eur J Clin Pharmacol 2011;67:601–12.10.1007/s00228-010-0959-2Search in Google Scholar

76. Shi HQ, Yang J, Zhang LQ, Lu HL, Chen B. The influence of CYP3A5*3 genotype on the pharmacokinetics of Chinese renal transplant patients through population pharmacokinetic method. Chin J Pharm 2013;44:218–85.Search in Google Scholar

77. Chen B, Yang WH, Zhang WX, Liu XX, Li J, Shen ZB. Population pharmacokinetics model of vancomycin in Chinese adult patients. Pharm Clin Res 2013;21:471–6.Search in Google Scholar

78. Cai WM, Chen B, Liu YX, Chu X. Dextromethorphan metabolic phenotyping in a Chinese population. Acta Pharmacol Sin 1997;18:441–4.Search in Google Scholar

79. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 1999;65:570–5.10.1016/S0009-9236(99)70077-9Search in Google Scholar

80. Kimiskidis VK, Niopas I, Firinidis PD, Kanaze FI, Gabrieli C, Kazis D, et al. Frequency distribution of dextromethorphan O-demethylation in a Greek population. Int J Clin Pharmacol Ther 2005;43:150–3.10.5414/CPP43150Search in Google Scholar PubMed

81. Tamminga WJ, Wemer J, Oosterhuis B, Weiling J, Wilffert B, de Leij LF, et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 1999;55:177–84.10.1007/s002280050615Search in Google Scholar PubMed

82. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284–95.Search in Google Scholar

83. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998;8:15–26.10.1097/00008571-199802000-00003Search in Google Scholar PubMed

84. Garcia-Barcelo M, Chow LY, Chiu HF, Wing YK, Lee DT, Lam KL, et al. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem 2000;46:1873.10.1093/clinchem/46.1.18Search in Google Scholar

85. Ishida S, Soyama A, Saito Y, Murayama N, Saeki M, Sai K, et al. Determination of CYP2D6 gene alleles by the CYP450 probe array using the Affymetrix GeneChip system: comparison with sequencing results. Drug Metab Pharmacokinet 2002;17:157–60.10.2133/dmpk.17.157Search in Google Scholar PubMed

86. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997;280:927–33.10.1016/S0022-3565(24)36462-6Search in Google Scholar

87. Sindrup SH, Brøsen K, Hansen MG, Aaes-Jørgensen T, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;15:11–7.10.1097/00007691-199302000-00002Search in Google Scholar

88. Chen B, Xu Y, Jiang T, Feng R, Sun J, Zhang W, et al. Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay. J Clin Pharm Ther 2013;38:504–11.10.1111/jcpt.12029Search in Google Scholar

89. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K. Frequencies of CYP2D6 variant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 2000;50:31–4.10.1046/j.1365-2125.2000.00209.xSearch in Google Scholar

90. Ji L, Pan S, Marti-Jaun J, Hanseler E, Rentsch K, Hersberger M. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem 2002;48:983–8.10.1093/clinchem/48.7.983Search in Google Scholar

91. Cai WM, Chen B, Zhang WX. Frequency of CYP2D6 *10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population. Clin Pharmacol Ther 2007;81:95–8.10.1038/sj.clpt.6100015Search in Google Scholar

92. Chen B, Zhang W, Fang J, Jin Z, Li J, Yu Z, et al. Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients. Xenobiotica 2009;39:931–8.10.3109/00498250903226025Search in Google Scholar

93. Shi HQ, Xu BM, Chen B. Relationship between different CYP3A5*3 genotype and sirolimus plasma concentration in Chinese renal transplant recipients. Chin J Pharm 2010;41:678–82.Search in Google Scholar

94. Liu XX, Chen B. The influence of genetic polymorphism of CYP3A5 and MDR1 on the pharmacokinetics of tacrolimus in Chinese liver transplantation patients. Chin J Clin Pharmacy 2014;23:283–7.Search in Google Scholar

95. Evans DA. N-acetyltransferase. Pharmacol Ther 1989;42: 157–234.10.1016/0163-7258(89)90036-3Search in Google Scholar

96. Lu JF, Cao XM, Liu ZH, Cao W, Guo LQ, Zhuo HT, et al. Genetic analysis of N-acetyltransferase polymorphism in a Chinese population. Acta Pharmacol Sin 1998;19:347–51.Search in Google Scholar

97. Chen B, Cai WM, Zhang WX. The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population. Eur J Clin Pharmacol 2006;62:355–9.10.1007/s00228-006-0110-6Search in Google Scholar PubMed

98. Chen B, Cao XM, Li JH. Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects. Drug Metab Drug Interact 2011;26:113–8.10.1515/DMDI.2011.016Search in Google Scholar

99. Hein DW, Ferguson RJ, Doll MA, Rustan TD, Gray K. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum Mol Genet 1994;3:729–34.10.1093/hmg/3.5.729Search in Google Scholar PubMed

100. Grant DM, Morike K, Eichelbaum M, Meyer UA. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 1990;85:968–72.10.1172/JCI114527Search in Google Scholar PubMed PubMed Central

101. Slinker BK, Glantz SA. Multiple linear regression is a useful alternative to traditional analyses of variance. Am J Physiol 1988;255:R353–67.10.1152/ajpregu.1988.255.3.R353Search in Google Scholar

102. Chen B, Cai WM, Li JH, Cao XM. Estimating N-acetyltransferase metabolic activity and pharmacokinetic parameters of isoniazid from genotypes in Chinese subjects. Clin Chim Acta 2009;405:23–9.10.1016/j.cca.2009.03.045Search in Google Scholar

103. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735–8.10.1073/pnas.84.21.7735Search in Google Scholar

104. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361–8.10.1146/annurev.pharmtox.39.1.361Search in Google Scholar

105. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55:3–29.10.1016/S0169-409X(02)00169-2Search in Google Scholar

106. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 2000;38:69–74.10.5414/CPP38069Search in Google Scholar PubMed

107. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22:7468–85.10.1038/sj.onc.1206948Search in Google Scholar PubMed

108. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003;13:481–94.10.1097/00008571-200308000-00006Search in Google Scholar PubMed

109. Chen B, Fang J, Zhang W, Jin Z, Yu Z, Cai W. Detection of C1236T, G2677T/A and C3435T polymorphism of MDR1 by amplification refractory mutation system PCR. J Clin Lab Anal 2009;23:110–6.10.1002/jcla.20299Search in Google Scholar PubMed PubMed Central